Alexander's, Inc. logo ALX - Alexander's, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 1
HOLD 0
SELL 1
STRONG
SELL 0
| PRICE TARGET: $212.00 DETAILS
HIGH: $212.00
LOW: $212.00
MEDIAN: $212.00
CONSENSUS: $212.00
DOWNSIDE: 10.46%

Stock News

Mousetraps: 7 High-Yield REITs Risking Dividend Cuts

Mousetraps: 7 High-Yield REITs Risking Dividend Cuts

High-yield 'mousetrap' REITs consistently underperform, with average returns lagging the VNQ by 1090–1380 bps due to dividend cuts and price declines. Dividend Safety grades of F indicate a roughly 40% chance of a cut within 12 months, making these REITs especially risky for income-focused investors. Nine REITs, including CLPR, BDN, CHCT, GOOD, NXRT, GNL, ALX, BRT, and AFCG, currently offer yields above 6.85% but have severe Dividend Safety concerns.

Oct 07, 2026 03:45 AM • seekingalpha.com
Alexander’s (NYSE:ALX) & Essential Properties Realty Trust (NYSE:EPRT) Head-To-Head Review

Alexander’s (NYSE:ALX) & Essential Properties Realty Trust (NYSE:EPRT) Head-To-Head Review

Alexander's (NYSE: ALX - Get Free Report) and Essential Properties Realty Trust (NYSE: EPRT - Get Free Report) are both real estate companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Analyst Recommendations This is a breakdown

Oct 06, 2026 06:14 AM • defenseworld.net
Head-To-Head Analysis: Tritax Big Box REIT (OTCMKTS:TTBXF) vs. Alexander’s (NYSE:ALX)

Head-To-Head Analysis: Tritax Big Box REIT (OTCMKTS:TTBXF) vs. Alexander’s (NYSE:ALX)

Alexander's (NYSE: ALX - Get Free Report) and Tritax Big Box REIT (OTCMKTS:TTBXF - Get Free Report) are both real estate companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Earnings and Valuation This table compares

Sep 03, 2026 11:29 PM • defenseworld.net
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer – – Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026 that further validate a biomarker-driven development strategy for evorpacept – – Strong enrollment momentum in Phase 1 clinical trial of ALX2004 in EGFR expressing solid tumors with initial safety data on-track for 2H 2026 – – Strengthened leadership team with the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Aug 06, 2026 04:00 AM • globenewswire.com
Alexander's Announces Second Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

Alexander's Announces Second Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

PARAMUS, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2026 with the U.S. Securities and Exchange Commission and issue its second quarter earnings release on Monday, August 3, 2026, before the New York Stock Exchange opens.

Jul 21, 2026 08:23 AM • globenewswire.com
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 500,000 shares of ALX Oncology's common stock to Michael Listgarten, General Counsel, on June 29, 2026 in connection with the commencement of his employment. Mr. Listgarten's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Listgarten to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

Jun 30, 2026 12:40 PM • globenewswire.com

Price Targets